Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Dig Dis ; 35(6): 541-547, 2017.
Article in English | MEDLINE | ID: mdl-29040986

ABSTRACT

BACKGROUND: Sofosbuvir plus ribavirin (RBV) therapy showed higher sustained virological response at 12 weeks after treatment (SVR12) than pegylated interferon (peg-IFN) plus RBV; however, liver function, fibrosis, and hepatocellular carcinoma markers have not been assessed so far. SUMMARY: Patients (n = 21) receiving Sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV were enrolled in this study. Changes in alanine aminotransferase (ALT) and α-fetoprotein (AFP) levels, platelet (PLT) counts, FIB-4, and aspartate aminotransferase-to-platelet ratio index (APRI) in both groups were assessed in patients achieving SVR12. Also, fibrosis regression was assessed using pathophysiological biomarkers, such as hyaluronic acid, bone morphogenetic protein 7 (BMP-7), and connective tissue growth factor (CTGF) in the Sofosbuvir plus RBV group. In both groups, while the reduction in ALT levels was significant that of AFP was not. Compared with the baseline, although serum PLT count at the end of treatment (EOT) was significantly higher in the Sofosbuvir plus RBV group, it was significantly lower in the peg-IFN plus RBV group. Although a significant decline in fibrosis markers such as FIB-4 and APRI was observed between the baseline and at EOT in the Sofosbuvir plus RBV group, no significant change of these markers was observed in the peg-IFN plus RBV group. Moreover, BMP-7 and CTGF were significantly lower at EOT than the baseline in the Sofosbuvir plus RBV group. Key Message: The treatment with Sofosbuvir plus RBV results in not only a higher SVR, but also improves the liver function and the degree of fibrosis.


Subject(s)
Hepacivirus/genetics , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/virology , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Sofosbuvir/therapeutic use , Antiviral Agents/therapeutic use , Biomarkers, Tumor/blood , Bone Morphogenetic Protein 7/blood , Carcinoma, Hepatocellular/blood , Carcinoma, Hepatocellular/drug therapy , Connective Tissue Growth Factor/blood , Drug Therapy, Combination , Female , Genotype , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/physiopathology , Humans , Liver Function Tests , Liver Neoplasms/blood , Liver Neoplasms/drug therapy , Middle Aged , Recombinant Proteins/therapeutic use , Sofosbuvir/administration & dosage , Sustained Virologic Response , Treatment Outcome , alpha-Fetoproteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...